ArticleAdvances in therapy2022

Pembrolizumab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A Cost-Effectiveness Analysis.

Youwen Zhu et al.PubMed ↗Publisher ↗

No numbers read from the abstract.